2020 ASCO Virtual Direct™ Highlights
Playback speed
10 seconds
2020 ASCO Update on Targeted Therapy in NSCLC: Is T-DXd a New Option for HER2+ Disease? Is Osimertinib Effective Enough in EGFRm Disease to Be Considered Practice Changing?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Ravi Salgia
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Ravi Salgia
272 views
August 13, 2020
Login to view comments.
Click here to Login
Lung
